Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (20022)	5/4/1998 3:07:00 PM
From: Torben Noerup Nielsen	Read Replies (2) \| Respond to of 32384

Mudcat, >Lgnd puts out mice model data on breast cancer and the stock doesn't >move. I'm pretty sure LGND's experiments were done on rats; not mice :-). I'd rate the rat model as slightly more realistic. ENMD is shooting up primarily because of the publicity. Somehow the news media has decided that this is the weapon that will finally allow us to wipe out cancer. Maybe anti-angiogenesis drugs will work as well in humans as they apparently do in naked mice. If this is the case, the cancer programs LGND has now won't be worth much. But the other programs are fine. And if these drugs really do wipe out cancer, I will take the loss on LGND and be fairly happy about it. It is a really nasty disease. Thanks, Torben

To: Mudcat who wrote (20022)	5/4/1998 3:18:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 32384

Mudcat, Torben's right. The ENMD news has been out since November. The price spike is due to the NYT article, and the extremely positive statements by Klausner and Watson. But the data they are commenting on has been public for some time. ENMD sat for a long time with its share price substantially unaffected ... If you believe in the company, the management, the funding, the products, the markets, and the technology, then don't worry if the market doesn't seem to value LGND the way you do. Your example of ENMD would support this approach.

To: Mudcat who wrote (20022)	5/4/1998 9:38:00 PM
From: Henry Niman	Respond to of 32384

Mudcat, I don't think that you have a good grasp of who does and doesn't appear on CNBC. As I recall, when LGND presented the breast cancer data, their price was "heading for $10". It ran from under 11 to over 16 and has now stabilized between 14 and 15, building a very nice flying platform.